¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2022³â Ãá°èÇмú´ëȸ ¹× Çп¬»ê ½ÉÆ÷Áö¾ö(1ÀÏÂ÷) : 2022-04-08

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
2022³â Ãá°èÇмú´ëȸ ¹× Çп¬»ê ½ÉÆ÷Áö¾ö(1ÀÏÂ÷) : 2022-04-08
±³À°ÀÏÀÚ : 2022-04-08
±³À°Àå¼Ò : ¿öÄ¿ÈúÈ£ÅÚ, ¼­¿ï  
±³À°ÁÖÁ¦ : (¿Â¶óÀÎ-¿ÀÇÁ¶óÀÎ ÇÏÀ̺긮µå) 2022³â Ãá°èÇмú´ëȸ ¹× Çп¬»ê ½ÉÆ÷Áö¾ö(1ÀÏÂ÷) 
ÁÖÃÖ±â°ü : ´ëÇѳ»ºÐºñÇÐȸ
´ã´çÀÚ : ³»ºÐºñÇÐȸ
¿¬¶ôó : 02-714-2428  
À̸ÞÀÏ : endo@endocrinology.or.kr      
±³À°Á¾·ù : ³»°ú      
Âü¼®¿¹»óÀοø : 800¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 28 ½Ã°£ 30ºÐ  
¼¼ºÎ¼ö°­·á : 150,000¿ø      
ºñ°í Àü¹®ÀÇ/ÀüÀÓÀÇ/±³¼ö/°³¿øÀÇ/±âÃÊÀÇÇÐÀÚ : 10¸¸¿ø (ºñȸ¿ø 15¸¸¿ø) Àü°øÀÇ/´ëÇпø»ý/±ºÀÇ°ü/°øÁߺ¸°ÇÀÇ/°£È£»ç/¿µ¾ç»ç/ÀÇ·á±â»ç/±âŸ : 5¸¸¿ø (ºñȸ¿ø 7¸¸¿ø) *¸¸ 65¼¼ ÀÌ»ó Æò»ýȸ¿ø : ¹«·á **Àü°øÀÇ, ´ëÇпø»ýÀ» Á¦¿ÜÇÑ Çлý : ¹«·á      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 04-08 Room 1 09:00~09:15 ³²°î ¹ÎÇå±â ±³¼öÀÇ ¹ßÀÚÃë: ºÎ½Å Áúȯ ºÐ¾ß  ±è¼º¿¬(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 04-08 Room 1 09:15~09:30 ³²°î ¹ÎÇå±â ±³¼öÀÇ ¹ßÀÚÃë: ´ç´¢º´ ºÐ¾ß  ¹Ú°æ¼ö(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 04-08 Room 1 09:30~09:45 ³²°î ¹ÎÇå±â ±³¼öÀÇ ¹ßÀÚÃë: Ä®½· ¹× °ñ´ë»ç ºÐ¾ß  ½ÅÂù¼ö(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 04-08 Room 1 09:45~10:00 ³²°î ¹ÎÇå±â ±³¼öÀÇ ¹ßÀÚÃë: ³úÇϼöü Áúȯ ºÐ¾ß  ±è¹Î¼±(¿ï»êÀÇ´ë) 
Åä·Ð 04-08 Room 1 10:00~10:30 Åä·Ð  () 
±³À°½Ã°£ 04-08 Room 2 09:00~09:20 Iso-dehydrozingerone Blocks RANKL-induced Differentiation of Monocyte/macrophage Lineage to Osteoclast by the Extreme Activation of NF-¥êB  ¹Ú±æÈ«(°í·ÁÀÇ´ë »ýÈ­ÇкÐÀÚ»ý¹°Çб³½Ç) 
±³À°½Ã°£ 04-08 Room 2 09:20~09:40 Bone Regeneration Using Bioceramics and Bioactive Molecules  ¹ÚÀDZÕ(°æºÏ´ëÇб³ Ä¡°ú´ëÇÐ ±¸°­º´¸®ÇÐ ¹× Àç»ýÀÇÇб³½Ç) 
±³À°½Ã°£ 04-08 Room 2 09:40~10:00 Biomaterials-based Delivery of Signaling Molecules and Cells for Bone Tissue Engineering  ½ÅÈï¼ö(ÇѾç´ëÇб³ »ý¸í°øÇаú) 
Åä·Ð 04-08 Room 2 10:00~10:30 Åä·Ð  () 
±³À°½Ã°£ 04-08 Room 3 09:00~09:20 Precision Diagnosis of Diabetic Complication Using Exosomal Multi-omics  ·ù¼ºÈ£(¼øõÇâÀÇ´ë SIMS) 
±³À°½Ã°£ 04-08 Room 3 09:20~09:40 ´ç´¢º´¼º½ÅÁõ¿¡¼­ ¼Òº¯ ¼¼Æ÷¹Û ¼ÒÆ÷ü miRNA ÇÁ·ÎÆÄÀϸµ ¹× ³×Æ®¿öÅ© °æ·ÎºÐ¼®   ÀÌ´ëÈ£(°¡ÃµÀÇ´ë) 
±³À°½Ã°£ 04-08 Room 3 09:40~10:00 Effect of Salivary Exosomal miRNA on Periodontitis with Insulin Resistance  ÀÌÇö½Â(Ãæ³²ÀÇ´ë) 
Åä·Ð 04-08 Room 3 10:00~10:30 Åä·Ð  () 
±³À°½Ã°£ 04-08 Room 4 09:00~09:20 Metformin and Aging   ±èÇýÁø(¾ÆÁÖÀÇ´ë) 
±³À°½Ã°£ 04-08 Room 4 09:20~09:40 Hormone Treatment of Postmenopausal Women  Ã¤Èñµ¿(¿ï»êÀÇ´ë »êºÎÀΰú) 
±³À°½Ã°£ 04-08 Room 4 09:40~10:00 Melatonin and Aging   ±è¹Ì°æ(ÀÎÁ¦ÀÇ´ë) 
Åä·Ð 04-08 Room 4 10:00~10:30 Åä·Ð  () 
È޽Ġ04-08  10:30~10:40 È޽Ġ () 
±³À°½Ã°£ 04-08 Room 1 10:40~11:00 COVID-19¿Í °©»ó¼±Áúȯ  ±ÇÇý¹Ì(°­ºÏ»ï¼ºº´¿ø ³»ºÐºñ³»°ú) 
±³À°½Ã°£ 04-08 Room 1 11:00~11:20 °©»ó¼±ÃÊÀ½ÆÄ ±Þ¿©È­   ÇѼö¿¬(»ï¼º¼­¿ïº´¿ø ¿µ»óÀÇÇаú) 
±³À°½Ã°£ 04-08 Room 1 11:20~11:40 Radiation Hazard of Radioiodine Therapy: Emotion and Science  ÆØÁøö(¼­¿ï´ëº´¿ø ÇÙÀÇÇаú) 
Åä·Ð 04-08 Room 1 11:40~12:10 Åä·Ð  () 
±³À°½Ã°£ 04-08 Room 2 10:40~11:00 Biochemical Mechanisms of Fuel Metabolism and the Physiological Relevance in Human Diseases  ÃÖµ¿¿í(Ãæ³²´ë »ýÈ­ÇÐ) 
±³À°½Ã°£ 04-08 Room 2 11:00~11:20 Developmental Programming of Immunity and Metabolism by Perinatal Endocrine Signal  È«ÁØ¿µ(¿¬¼¼´ëÇб³ »ý¸í°øÇÐ) 
±³À°½Ã°£ 04-08 Room 2 11:20~11:40 Irisin, its Receptor and the Links between Exercise and Health  ±èÇö¿ì(Harvard Medical School / 3¿ù KAIST »ý¸í°úÇаú ÀÓ¿ë) 
Åä·Ð 04-08 Room 2 11:40~12:10 Åä·Ð  () 
±³À°½Ã°£ 04-08 Room 3 10:40~11:00 Update on the ADA Diabetes Treatment Guideline 2022  Á¤Ã¢Èñ(¿ï»êÀÇ´ë ¼­¿ï¾Æ»êº´¿ø) 
±³À°½Ã°£ 04-08 Room 3 11:00~11:20 Efficacy and Safety of Evogliptin in Patients with Type2 Diabetes and Non-alcoholic Fatty Liver Disease  ÇãÁöÇý(ÇѸ²ÀÇ´ë ÆòÃ̼º½Éº´¿ø) 
±³À°½Ã°£ 04-08 Room 3 11:20~11:40 Combination therapy of oral antidiabetic drugs involving evogliptin and the risk of cardiovascular events in patients with type 2 diabetes mellitus  ±è³²ÈÆ(°í·ÁÀÇ´ë °í´ë¾È¾Ïº´¿ø) 
Åä·Ð 04-08 Room 3 11:40~12:10 Åä·Ð  () 
±³À°½Ã°£ 04-08 Room 4 10:40~11:00 Genetic Approach to Skeletal Dysplasia  °íÁ¤¹Î(¼­¿ïÀÇ´ë ¼Ò¾Æû¼Ò³â°ú) 
±³À°½Ã°£ 04-08 Room 4 11:00~11:20 Treatment of FGF23-related Hypophosphatemic Diseases  À̽ÂÇö(¿¬¼¼ÀÇ´ë ³»ºÐºñ³»°ú) 
±³À°½Ã°£ 04-08 Room 4 11:20~11:40 Hypophosphatasia  ¹®ÁØÈ£(¼­¿ïÀÇ´ë ³»ºÐºñ³»°ú) 
Åä·Ð 04-08 Room 4 11:40~12:10 Åä·Ð  () 
È޽Ġ04-08  12:10~12:20 È޽Ġ () 
±³À°½Ã°£ 04-08 Room 1 12:20~12:40 My Clinical Experiences of Evolocumab in Endocrinology  ½Åµ¿¿±(¿¬¼¼ÀÇ´ë ¼¼ºê¶õ½ºº´¿ø) 
±³À°½Ã°£ 04-08 Room 1 12:40~13:00 Clinical Significance of TIR and the Latest Comparative Study of Second-generation Basal Insulin  ±è±Ô¸®(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 04-08 Room 2 12:20~12:40 How to find the Optimal Combination Therapy for Patients with Type 2 Diabetes  À̽Âȯ(°¡Å縯ÀÇ´ë ¼­¿ï¼º¸ðº´¿ø) 
±³À°½Ã°£ 04-08 Room 2 12:40~13:00 New Lipid Therapy Option for Low & Moderate Risk ASCVD Patients  ±è»ó¿ë(Á¶¼±ÀÇ´ë) 
±³À°½Ã°£ 04-08 Room 3 12:20~12:40 KDA/ADA ÃֽŠÁø·áÁöħ°ú ÇÔ²² »ìÆì º» Ç÷´çº¯µ¿¼º °ü¸®ÀÇ Á߿伺  Ãְ湬(°í·ÁÀÇ´ë °í´ë±¸·Îº´¿ø) 
±³À°½Ã°£ 04-08 Room 3 12:40~13:00 Cutting Edge Care of Pitavastatin with Ezetimibe Combination Therapy  ÀÌÀçÇõ(ÇѾçÀÇ´ë ¸íÁöº´¿ø ³»ºÐºñ³»°ú) 
½Ä»ç 04-08  13:00~13:20 ½Ä»ç  () 
È޽Ġ04-08  13:20~13:40 È޽Ġ () 
±³À°½Ã°£ 04-08 Room 1 13:40~14:20 Role of Lysosomal Stress & Lysosome Stress Response in Metabolic Syndrome and Diabetes  À̸í½Ä(¼øõÇâ´ëÇб³ ÀÇ»ý¸í¿¬±¸¿ø (SIMS) (¼®Á ±³¼ö)) 
±³À°½Ã°£ 04-08 Room 1 14:20~14:40 My Journey to (Para)thyroid Diseases  À̽ÃÈÆ(°¡ÃµÀÇ´ë) 
È޽Ġ04-08  14:40~14:50 È޽Ġ () 
±³À°½Ã°£ 04-08 Room 1 14:50~15:10 Super-hero Antibodies against Osteoporosis (Efficacy of Denosumab and Romosozumab)  ¾È¼ºÈñ(ÀÎÇÏÀÇ´ë) 
±³À°½Ã°£ 04-08 Room 1 15:10~15:30 Questions and Facts Regarding Denosumab Discontinuation  ±è¹üÁØ(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 04-08 Room 1 15:30~15:50 Real-world Effectiveness of Romosozumab with Case Review  È«³²±â(¿¬¼¼ÀÇ´ë) 
Åä·Ð 04-08 Room 1 15:50~16:20 Åä·Ð  () 
±³À°½Ã°£ 04-08 Room 2 14:50~15:05 ¼Ò¾Æ¿¡¼­ÀÇ ¿©¼ºÇü À¯¹æÀÇ ÀÓ»óÀû ÀÇ¹Ì - ¼ºÁ¶¼÷Áõ°ú ¿©¼ºÇü À¯¹æ  Ã¤Çö¿í(¿¬¼¼ÀÇ´ë °­³²¼¼ºê¶õ½ºº´¿ø ¼Ò¾Æ³»ºÐºñ³»°ú) 
±³À°½Ã°£ 04-08 Room 2 15:05~15:20 ¿©¼ºÇü À¯¹æÀÇ ¿µ»óÀÇÇÐÀû Áø´Ü  À±Á¤Çö(¿¬¼¼ÀÇ´ë ¿µ»óÀÇÇаú) 
±³À°½Ã°£ 04-08 Room 2 15:20~15:35 Evaluation and Management of Gynecomastia in Adults  °ø¼ºÇý(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 04-08 Room 2 15:35~15:50 ¿©¼ºÇüÀ¯¹æÁõ ¼ö¼úÀû Ä¡·áÀÇ ÃÖ½ÅÁö°ß   ¹ÎÈ£±Õ(À¯¹Ì³ë ¿Ü°úÀÇ¿ø) 
Åä·Ð 04-08 Room 2 15:50~16:20 Åä·Ð  () 
±³À°½Ã°£ 04-08 Room 3 14:50~15:10 Best Candidate Patients for Abs & siRNA against PCSK9  ÀÌ¿øÀç(¼­¿ïÀÇ´ë ºÐ´ç¼­¿ï´ëº´¿ø ¼øȯ±â³»°ú) 
±³À°½Ã°£ 04-08 Room 3 15:10~15:30 New Modulators of LDLR-independent Pathways  ÀÌÂùÁÖ(¿¬¼¼ÀÇ´ë ½ÉÀå³»°ú) 
±³À°½Ã°£ 04-08 Room 3 15:30~15:50 Metabolic Consequences of New Lipid Lowering Drugs: Good or Bad?  ¼­¼ºÈ¯(µ¿¾ÆÀÇ´ë µ¿¾Æ´ëº´¿ø ³»ºÐºñ³»°ú) 
Åä·Ð 04-08 Room 3 15:50~16:20 Åä·Ð  () 
±³À°½Ã°£ 04-08 Room 4 14:50~15:10 Multi-Center, Non-Randomized, Parallel Group, Non-Inferiority Study to Compare the Efficacy of No Radioactive Iodine Remnant Ablation to Remnant Ablation Treatment in Low- to Intermediate-Risk of Papillary Thyroid Cancer: The MOREthyroid Trial  ÀÌÀº°æ(±¹¸³¾Ï¼¾ÅÍ) 
±³À°½Ã°£ 04-08 Room 4 15:10~15:30 Liver X Receptor ¥â Related to Tumor Progression and Ribosome Gene Expression in Papillary Thyroid Cancer  Á¶¿µ¼®(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 04-08 Room 4 15:30~15:50 Fasting Plasma Glucose Level Independently Predicts the Mortality of Patients with Coronavirus Disease 2019 Infection: A Multicenter, Retrospective Cohort Study  ¹®Áؼº(¿µ³²ÀÇ´ë) 
Åä·Ð 04-08 Room 4 15:50~16:20 Åä·Ð  () 
±³À°½Ã°£ 04-08 Room 5 14:50~15:10 Obesity Clinic Setting  ÀÌ¿ëÈ£(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 04-08 Room 5 15:10~15:30 Use of DXA for Body Composition  ±èųâ(ÀÎÁ¦ÀÇ´ë) 
±³À°½Ã°£ 04-08 Room 5 15:30~15:50 Use of Bioelectrical Impedance Analysis  ÀÓ¼ö(¼­¿ïÀÇ´ë) 
Åä·Ð 04-08 Room 5 15:50~16:20 Åä·Ð  () 
È޽Ġ04-08  16:20~16:30 È޽Ġ () 
±³À°½Ã°£ 04-08 Room 1 16:30~16:50 ³»ºÐºñÇÐȸÀÇ ¿ª»ç ¡®40³â»ç¡¯  ±èµ¿¼±(ÇѾçÀÇ´ë) 
±³À°½Ã°£ 04-08 Room 1 16:50~17:10 ³»ºÐºñÇÐȸÀÇ ¾÷Àû ¡®40³â°£ÀÇ Çй®Àû ¼ºÃ롯  ÀÌÀºÁ÷(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 04-08 Room 1 17:10~17:30 ³»ºÐºñÇÐȸÀÇ ¹Ì·¡ ¡®¿ì¸®°¡ °¡¾ß Çұ桯  À¯¼øÁý(°¡Å縯ÀÇ´ë) 
Åä·Ð 04-08 Room 1 17:30~18:00 Åä·Ð  () 
±³À°½Ã°£ 04-08 Room 2 16:30~16:50 How DPP4Is May Address the Treatment Strategies  ¿ÀÅÂÁ¤(¼­¿ïÀÇ´ë ºÐ´ç¼­¿ï´ëÇб³º´¿ø) 
±³À°½Ã°£ 04-08 Room 2 16:50~17:10 Keep Your Confidence on Type 2 DM in Broad Range of Patients  ±èÇý¼ø(°è¸íÀÇ´ë °è¸í´ëÇб³ µ¿»êº´¿ø) 
±³À°½Ã°£ 04-08 Room 2 17:10~17:30 The Latest Evidence of SGLT2 Inhibitors for Patients with Type 2 Diabetes  ¹Ú¼¼Àº(¼º±Õ°üÀÇ´ë °­ºÏ»ï¼ºº´¿ø) 
Åä·Ð 04-08 Room 2 17:30~18:00 Åä·Ð  () 
±³À°½Ã°£ 04-08 Room 3 16:30~17:00 °©»ó¼±ÀÚ°¡Ç×ü°¡ ÀӽŠ¹× ÀӽŠÇÕº´Áõ¿¡ ¹ÌÄ¡´Â ¿µÇâ  ±èÁøÈ­(Á¶¼±ÀÇ´ë) 
±³À°½Ã°£ 04-08 Room 3 17:00~17:30 ÀӽŠÀüÈÄ °©»ó¼±±â´ÉÀúÇÏÁõÀÇ Áø´Ü ¹× Ä¡·á  ¾ÈÈ­¿µ(Áß¾ÓÀÇ´ë) 
Åä·Ð 04-08 Room 3 17:30~18:00 Åä·Ð  () 
±³À°½Ã°£ 04-08 Room 5 16:30~16:50 Appetite Regulation: Role of Brain and Peripheral Signals in Obesity  ³ëÀº(°í·ÁÀÇ´ë °í·Á´ëÇб³ ±¸·Îº´¿ø ³»ºÐºñ³»°ú) 
±³À°½Ã°£ 04-08 Room 5 16:50~17:10 Role of Phentermine and Qsymia in Obesity Management  ±èº¸¿¬(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 04-08 Room 5 17:10~17:30 Role of Incretin-based Therapy in Obesity Management: Liraglutide, Semaglutide, Tirzepatide  ¼ÕÀå¿ø(°¡Å縯ÀÇ´ë) 
Åä·Ð 04-08 Room 5 17:30~18:00 Åä·Ð  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2022³â Ãá°èÇмú´ëȸ ¹× Çп¬»ê ½ÉÆ÷Áö¾ö(1ÀÏÂ÷) : 2022-04-08""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û Çѱ¹ÀÇÇб³À°ÇÐȸ 2022³âµµ ½ÅÀÓ±³¼ö ¿öÅ©¼ó(2ÀÏÂ÷) : 2022-04-08
´ÙÀ½±Û (¿Â¶óÀÎ) 1Çбâ À̺ñÀÎÈÄ°ú Áö¿ªÀÇ»çÁý´ãȸ(À̺ñÀÎÈÄ°ú ¿µ¿ª¿¡¼­ Àü½Å ½ºÅ×·ÎÀÌµå »ç¿ë¹ý: °íÇ÷¾Ð, ´ç´¢ ȯÀڵ鿡¼­ °í¿ë·®, Àå±â°£ Ä¡·á ½Ã ȯÀÚ ¸ð´ÏÅ͸µ ¹æ¹ý) : 2022-04-07
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20893 ¼­¿ï ´ëÇѳúÁ¹ÁßÇÐȸ 6¿ù º¸¼ö±³À° : 2024-06-30 0 105 2024-05-27
20892 ¼­¿ï (¿Â¶óÀÎ)Á¦22Â÷ ¼­¿ïƯº°½ÃÀÇ»çȸ Çмú´ëȸ : 2024-06-30 0 6 2024-05-27
20891 °æ±â (¿Â¶óÀÎ)Á¦21Â÷ °æ±âµµÀÇ»çȸ ¿Â¶óÀÎ Çмú´ëȸ : 2024-06-30 0 8 2024-05-27
20890 Àü³² 2024³â ´ëÇÑ´ëÀåÇ×¹®ÇÐȸ ¿¬¼ö°­Á : 2024-06-30 0 6 2024-05-27
20889 Ãæ³² ´ëÇÑÁ¤Çü¿Ü°úÃÊÀ½ÆÄÇÐȸ - Á¦19Â÷ Ãá°èÇмú´ëȸ ¹× Á¦38Â÷ ±Ù°ñ°Ý°è ÃÊÀ½ÆÄ¿öÅ©¼¥ (Basic Course) : 2024-06-30 0 3 2024-05-27
20888 ºÎ»ê Á¦3ȸ ´ëÇÑÅõ¼®Çùȸ ºÎ»êÁöȸ ½ÉÆ÷Áö¾ö : 2024-06-29 0 1 2024-05-27
20887 ¼­¿ï Çѱ¹ÁöÁú¤ýµ¿¸Æ°æÈ­ÇÐȸ Á¦7ȸ A to Z (Atherosclerosis to Zero) ¿¬¼ö°­Á ÇÁ·Î±×·¥ : 2024-06-29 0 1 2024-05-27
20886 °æ±â 2024³âµµ ³²¾çÁÖ½ÃÀÇ»çȸ Çмú´ëȸ : 2024-06-29 0 1 2024-05-27
20885 ¼­¿ï (¿Â¶óÀÎ)Á¦14ȸ ´ëÇÑ°¨¿°ÇÐȸ Æò»ý±³À° ÇÁ·Î±×·¥ °¨¿°Áúȯ ÃÖ½ÅÁö°ß : 2024-06-29 0 1 2024-05-27
20884 ¼­¿ï Á¦24Â÷ ´ëÇѽÅÀåÇÐȸ ½ÅÀ̽Ŀ¬±¸È¸ ¿¬¼ö°­Á : 2024-06-29 0 1 2024-05-27
20883 ¼­¿ï 2024 ¼±Ãµ¼º Ⱦ°æ¸· Å»Àå ÄÚȣƮ (K-CDH) ±³À°¼¼¹Ì³ª : 2024-06-29 0 1 2024-05-27
20882 ¼­¿ï 2024 ¿©¼º½ÉÀåÁúȯ¿¬±¸È¸ ÇÏ°è ½ÉÆ÷Áö¾ö : 2024-06-29 0 1 2024-05-27
20881 °­¿ø 2024 ³âµµ Á¤Çü¿Ü°úÇб³½Ç °³¿øÀÇ¿¬¼ö°­Á : 2024-06-29 0 1 2024-05-27
20880 ¼­¿ï (¿Â¶óÀÎ) 2024 ¸¶Æ÷±¸ÀÇ»çȸ ¿Â¶óÀÎ Çмú´ëȸ : 2024-06-29 0 1 2024-05-27
20879 ¼­¿ï Á¦10ȸ ¿ëºÀÀÇÇÐȸ Çмú´ëȸ : 2024-06-29 0 1 2024-05-27
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷